Minretumomab Explained

Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2] [3] Apparently, it never got past Phase I clinical trials for this purpose.[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric and humanized minretumomab,[5] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[6]

Radiopharmaceuticals

Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[7]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (131I) and lutetium (177Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[8]

Notes and References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information . 13 . 3 . 1999 .
  2. Web site: TAG-72 antigen . NCI Dictionary of Cancer Terms . National Cancer Institute . 2011-02-02 .
  3. Scott AM, Wolchok JD, Old LJ . Antibody therapy of cancer . Nature Reviews. Cancer . 12 . 4 . 278–87 . March 2012 . 22437872 . 10.1038/nrc3236 . 205469234 .
  4. Web site: Studies found for: CC49 . ClinicalTrials.gov .
  5. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW . Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72 . Cancer . 116 . 4 Suppl . 1059–66 . February 2010 . 20127951 . 4498458 . 10.1002/cncr.24793 .
  6. Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V . 6 . Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT) . Bioconjugate Chemistry . 17 . 2 . 410–8 . 2006 . 16536473 . 10.1021/bc0503521 .
  7. Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J . 6 . Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay . Cancer Research . 56 . 22 . 5293–8 . November 1996 . 8912871 .
  8. Book: Biotherapy . registration . Paula . Trahan Rieger . vanc . Jones and Bartlett . 2nd . 2001 . 334–335 . 0-7637-1428-3.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Minretumomab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.